The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
125277151 12527715 1 I 20130614 20131004 20160705 20160705 EXP GB-PFIZER INC-1950866 PFIZER 30.00 YR F Y 0.00000 20160705 MD GB GB

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
125277151 12527715 1 PS DOCETAXEL. DOCETAXEL 1 Intravenous (not otherwise specified) 150 MG, CYCLIC: FREQ: 1 WEEK; INTERVAL: 3. UNK 22234 150 MG SOLUTION FOR INJECTION
125277151 12527715 2 SS DOCETAXEL. DOCETAXEL 1 Unknown 150 MG, FREQ: 1WEEK; INTERVAL: 3. UNK 22234 150 MG SOLUTION FOR INJECTION
125277151 12527715 3 C DEXAMETHASONE. DEXAMETHASONE 1 8 MG, UNK 0 8 MG
125277151 12527715 4 C DEXAMETHASONE. DEXAMETHASONE 1 UNK 0
125277151 12527715 5 C GLYCEROL GLYCERIN 1 Rectal UNK 0 SUPPOSITORY
125277151 12527715 6 C HYPROMELLOSE HYPROMELLOSES 1 UNK 0 SUPPOSITORY
125277151 12527715 7 C METOCLOPRAMIDE. METOCLOPRAMIDE 1 10 MG, UNK 0 10 MG
125277151 12527715 8 C METOCLOPRAMIDE. METOCLOPRAMIDE 1 10 MG, UNK 0 10 MG
125277151 12527715 9 C ONDANSETRON ONDANSETRON 1 8 MG, UNK 0 8 MG
125277151 12527715 10 C PERTUZUMAB PERTUZUMAB 1 Intravenous (not otherwise specified) 420 MG, FREQ: 1 WEEK; INTERVAL: 3. 1107243/1106568 0 420 MG
125277151 12527715 11 C PERTUZUMAB PERTUZUMAB 1 Intravenous (not otherwise specified) 840 MG, FREQ: 1 TOTAL; INTERVAL: 1. 1107243/1106568 0 840 MG
125277151 12527715 12 C PERTUZUMAB PERTUZUMAB 1 Intravenous (not otherwise specified) 8 MG/KG, FREQ: 1 WEEK; INTERVAL: 3. 1107243/1106568 0 8 MG/KG
125277151 12527715 13 C TRASTUZUMAB TRASTUZUMAB 1 Intravenous (not otherwise specified) 840 MG, FREQ:1 TOTAL; INTERVAL: 1. 0 840 MG
125277151 12527715 14 C TRASTUZUMAB TRASTUZUMAB 1 Intravenous (not otherwise specified) 420 UNK, FREQ: 1 WEEK; INTERVAL: 3. 0 420 MG

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
125277151 12527715 1 HER-2 positive breast cancer
125277151 12527715 3 Premedication
125277151 12527715 5 Product used for unknown indication
125277151 12527715 6 Product used for unknown indication
125277151 12527715 7 Product used for unknown indication
125277151 12527715 9 Product used for unknown indication
125277151 12527715 10 HER-2 positive breast cancer
125277151 12527715 13 HER-2 positive breast cancer

Outcome of event

Event ID CASEID OUTC COD
125277151 12527715 HO

Reactions reported

Event ID CASEID DRUG REC ACT PT
125277151 12527715 Febrile neutropenia
125277151 12527715 Neutropenic sepsis

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
125277151 12527715 1 20130605 0
125277151 12527715 2 20130828 0
125277151 12527715 3 20130604 20130606 0
125277151 12527715 4 20130625 20130627 0
125277151 12527715 7 20130605 20130612 0
125277151 12527715 8 20130626 20130703 0
125277151 12527715 9 20130626 20130627 0
125277151 12527715 11 20130605 20130605 0
125277151 12527715 12 20130605 20130605 0
125277151 12527715 13 20130605 20130605 0
125277151 12527715 14 20130605 0